Following discussion with the Scottish Medicines Consortium (SMC) Janssen has requested that the SMC decision not to recommend the use of Zytiga (abiraterone acetate) before chemotherapy for men with advanced prostate cancer in Scotland is referred to an Independent Review Panel.

This follows publication of the SMC Detailed Advice Document on 9 February 20151 that did not recommend the use of Zytiga® (abiraterone acetate) with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.

For more details, go to: http://www.firstwordpharma.com/node/1275429#axzz3XNNES0oe